MHRA Approves New Immunotherapy for Bladder Cancer
Approval applies to patients who are either ineligible for or decline cystectomy.
Inbakicept is administered in combination with BCG. It is not a replacement for BCG but acts as a complementary agent. The therapy enhances immune system activity by stimulating CD8+ T cells and natural killer cells, while avoiding the activation of regulatory T cells.
Durable Response Demonstrated in Clinical Trial
The approval was supported by data from the phase 2/3 QUILT-3.032 trial, which enrolled patients with BCG-unresponsive NMIBC with CIS.
The trial showed a complete response (CR) rate of 71%, with a median duration of 26.6 months. Among patients achieving CR, 58% maintained it for at least 12 months, and 40% remained disease-free at 24 months. Overall, 62% of patients with CIS achieved CR during treatment. The treatment also demonstrated a significant bladder-sparing effect, with a 90% probability of avoiding cystectomy in responders at 24 months.
Treatment involves direct instillation into the bladder via catheter. Patients receive weekly induction doses for 6 weeks, followed by maintenance doses at months 4, 7, 10, 13, and 19.
Safety Profile
The most common adverse events were urinary in nature and included dysuria, haematuria, urinary frequency, and urinary tract infections. Most were mild to moderate in severity.
Dr Patrick Soon-Shiong, executive chairman and global chief scientific officer at ImmunityBio, said the therapy offers 'a meaningful option for BCG-unresponsive NMIBC.'
The approval was granted through the International Recognition Procedure, with Serum Life Science Europe GmbH as the marketing authorisation holder.
Full prescribing information, including the Patient Information Leaflet and Summary of Product Characteristics, will be published on the MHRA website within 7 days of approval.
Healthcare professionals and patients are encouraged to report any adverse events through the Yellow Card scheme.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Hot flush pill gets green light for UK use
Women will be able to access a daily pill for hot flushes during menopause after it was given the green light for UK use. The Medicines and Healthcare products Regulatory Agency (MHRA) said it is the first regulator in the world to approve elinzanetant, also known as Lynkuet. The treatment, made by Bayer, can be given to women who have vasomotor symptoms, also known as hot flushes, as an alternative to hormone replacement therapy (HRT). HRT can help relieve most menopause and perimenopause symptoms, including hot flushes. But not all patients want or are able to take hormone treatments. At present elinzanetant is not available on the NHS but the green light from the MHRA means that it can be purchased privately in the UK. It is to be considered by the NHS spending watchdog, the National Institute for Health and Care Excellence. Hot flushes and night sweats are one of the most common symptoms of menopause. It is understood that as oestrogen levels decline around menopause, the body's temperature regulation system can be disrupted when certain brain cells become overactive. The new treatment, which is a non-hormonal medication, works by calming these signals in the brain. Clinical trial data showed that the drug was safe and well tolerated and reduced hot flushes compared with a dummy drug, also known as a placebo. You may not have reached #menopause if you're experiencing headaches, night sweats, weight gain, anxiety and depression – but you may be #perimenopausal. Take a look on our website for more information 👉 — Patient (@patient) May 22, 2023 It was also linked to fewer sleep disturbances and women taking it reported a better quality of life compared with those taking the placebo. 'Hot flushes and night sweats associated with menopause can have a significant negative impact on quality of life,' said Julian Beach, the MHRA's interim executive director of healthcare quality and access. 'We are therefore pleased to announce our approval of elinzanetant, which has met the MHRA's standards for safety, quality and effectiveness. 'Elinzanetant offers a non-hormonal alternative for those who may not be able to, or prefer not to, take hormone-based therapies. 'As with all licensed medicines, we will continue to monitor its safety closely as it becomes more widely used.' Women usually go through the menopause when they are aged between 45 and 55, though it can start sooner. During the menopause a woman's periods stop due to lower hormone levels. Menopause and perimenopause can cause symptoms including anxiety, mood swings, brain fog, hot flushes and irregular periods.
Yahoo
an hour ago
- Yahoo
Support group for mums from different ethnicities
A weekly group aimed at supporting mothers from different ethnicities will launch after one mum said she "never fitted in" at other groups. Carolyn Nansubuga, a Cheltenham mother-of-four, attended several groups following the birth of her youngest child, now 20 months, but said she struggled as she "never had anything in common with the other mums". Lives of Colour, a Gloucestershire-based race equity charity, will launch the Mothers of Colour group at Aspire Foundation, Cheltenham on Thursday, in partnership with the NHS perinatal maternity unit. Florence Nyasamo, charity founder, said the partnership will allow the health needs of mothers from all ethnicities to be met. More news stories for Gloucestershire Listen to the latest news for Gloucestershire National audit programme "Mothers and Babies: Reducing Risk through Audits, External" (MBRRACE-UK) found maternal deaths among black women were nearly three times higher compared with those of white women in 2020-22. The Mothers of Colour group will cover newborn care, mental wellness, and maternal health. Ms Nansubuga said, at the sessions, she hopes to meet mothers who "understand the cultural nuances" she experiences after not "fitting in" previously. "Groups are meant to give you rest from the mundane things of motherhood you've been going through at home so, when you go there, you have to feel welcome," she said. "But it's not just me, even my baby would think 'I don't look like everybody else here'. "When I heard about this group starting up I was super excited because, finally, we have the chance to attend a baby group and be ourselves." Ms Nyasamo said it can be hard for women who have moved from another country to understand the "small nuances" at groups in the UK. "It's nice to go into a space where you can just be," she said. "We know with the NHS partnership, if we need a midwife or health visitor to come and have a conversation, then we've already got those connections. "Whatever the women will ask for, we'll do our best to make sure their needs are met." Mothers of Colour is open to women of all ethnicities. Follow BBC Gloucestershire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630. Postnatal support group set up for black mothers Letter scheme aims to give voice to black mums Maternity care for black women must improve - MP Lives of Colour
Fox News
2 hours ago
- Fox News
Massive bee swarm sends three people to hospital in critical condition, 24 injured
A buzzing commotion has disrupted a picturesque town this summer. A swarm of bees left 24 people injured in an unusual attack on Sunday, The Associated Press (AP) reported. Those walking through Aurillac, a quaint French community, were stung over a 30-minute period, with three people in critical condition evacuated to a hospital. Some 26,000 people were living in the alp town in 2022, according to the French National Institute of Statistics and Economic Studies. Aurillack is located in the Auvergne-Rhône-Alpes region of France. Pierre Mathonier, mayor of Aurillac, told a local broadcaster that those who were left in critical condition are improving, AP reported. One victim was a 78-year-old who suffered cardiorespiratory arrest and had to be resuscitated. That individual is now in stable condition, while the other two are said to be in "good health," per the mayor. Mathonier added the attack could have been related to the bees becoming more aggressive over the years. Over a decade ago, Asian hornets were harassing a beehive that was on the roof terrace of a downtown hotel, he told AP. Lt. Col. Michel Cayla, who runs the local fire services, said the attack was "impressive" and he has never seen an attack of this scale. Cayla told French broadcaster TF1, "In terms of the number of victims, the panic among the people and the severity of some of the injuries, it was impressive," as AP reported. Bee sting symptoms are mostly "minor." Victims can experience instant, sharp, burning pain, as well as a welt and swelling, according to the Mayo Clinic. The CDC predicted an annual average of 62 deaths due to bee and hornet stings between 2000-2017 in the United States. The beehive has been removed and relocated outside the town, according to AP.
